In Vitro Cytotoxicity and In Vivo Antitumor Activity of Lipid Nanocapsules Loaded with Novel Pyridine Derivatives
Open Access
- 16 June 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (6) , 1755
Abstract
This study demonstrates high drug-loading of novel pyridine derivatives (S1–S4) in lipid- and polymer-based core–shell nanocapsules (LPNCs) for boosting the anticancer efficiency and alleviating toxicity of these novel pyridine derivatives. The nanocapsules were fabricated using a nanoprecipitation technique and characterized for particle size, surface morphology, and entrapment efficiency. The prepared nanocapsules exhibited a particle size ranging from 185.0 ± 17.4 to 223.0 ± 15.3 nm and a drug entrapment of >90%. The microscopic evaluation demonstrated spherical-shaped nanocapsules with distinct core–shell structures. The in vitro release study depicted a biphasic and sustained release pattern of test compounds from the nanocapsules. In addition, it was obvious from the cytotoxicity studies that the nanocapsules showed superior cytotoxicity against both MCF-7 and A549 cancer cell lines, as manifested by a significant decrease in the IC50 value compared to free test compounds. The in vivo antitumor efficacy of the optimized nanocapsule formulation (S4-loaded LPNCs) was investigated in an Ehrlich ascites carcinoma (EAC) solid tumor-bearing mice model. Interestingly, the entrapment of the test compound (S4) within LPNCs remarkably triggered superior tumor growth inhibition when compared with either free S4 or the standard anticancer drug 5-fluorouracil. Such enhanced in vivo antitumor activity was accompanied by a remarkable increase in animal life span. Furthermore, the S4-loaded LPNC formulation was tolerated well by treated animals, as evidenced by the absence of any signs of acute toxicity or alterations in biochemical markers of liver and kidney functions. Collectively, our findings clearly underscore the therapeutic potential of S4-loaded LPNCs over free S4 in conquering EAC solid tumors, presumably via granting efficient delivery of adequate concentrations of the entrapped drug to the target site.Keywords
Funding Information
- Prince Sattam bin Abdulaziz University (PSAU/2023/R/1444, PNURSP2023R205, RSPD2023R620)
- Princess Nourah Bint Abdulrahman University (PSAU/2023/R/1444, PNURSP2023R205, RSPD2023R620)
- King Saud University (PSAU/2023/R/1444, PNURSP2023R205, RSPD2023R620)
This publication has 47 references indexed in Scilit:
- The antiproliferative effect of indomethacin-loaded lipid-core nanocapsules in glioma cells is mediated by cell cycle regulation, differentiation, and the inhibition of survival pathwaysInternational Journal of Nanomedicine, 2013
- A new method for determining acute toxicity in animal modelsToxicology International, 2013
- Poly(Lactide-co-Glycolide) Nanocapsules Containing Benzocaine: Influence of the Composition of the Oily Nucleus on Physico-Chemical Properties and Anesthetic ActivityPharmaceutical Research, 2011
- Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low- and middle-income countriesAnnals of Oncology, 2011
- Recent advances in tumor vasculature targeting using liposomal drug delivery systemsExpert Opinion on Drug Delivery, 2009
- Lipid nanocapsules: A new platform for nanomedicineInternational Journal of Pharmaceutics, 2009
- Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor modelJournal of Controlled Release, 2009
- Mechanism of nanocapsules formation by the emulsion–diffusion processJournal of Colloid and Interface Science, 2008
- Liver enzyme alteration: a guide for cliniciansCanadian Medical Association Journal, 2005
- Nanocapsule formation by interfacial polymer deposition following solvent displacementInternational Journal of Pharmaceutics, 1989